Quick Reads | The Pulse of ACC
ACC Joining Forces With BioIntelliSense Around Remote Cardiac Care
The ACC and BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, have formed a strategic collaboration that combines innovative medical-grade wearable devices and data science to advance remote patient monitoring programs for cardiac care. The ACC will also offer the BioButton COVID-19 Screening Solution to provide an added layer of safety at ACC.21 in Atlanta in May.
ACC Names Jian'an Wang Inaugural Editor-in-Chief of JACC: Asia
Jian'an Wang, MD, PhD, FACC, has been named the inaugural editor-of-chief of JACC: Asia, the ACC's first region-specific, open access cardiovascular journal with original peer-reviewed content. The Journal will publish original manuscripts and clinical practice guidelines specific to East Asian populations and by Asian authors.
Wang is a physician scientist who serves as the chair of the Heart Center at the Second Affiliated Hospital at Zhejiang University School of Medicine in China. He is also a professor and associate dean at Zhejiang University School of Medicine.
New TRANSFORM: ACS Program Aims to Optimize ACS Care
The ACC, in collaboration with Amgen and Veradigm, have announced a new national study to transform care for acute coronary syndrome (ACS) patients at risk for future cardiovascular events. TRANSFORM: Accelerating Lipid Lowering Post ACS (TRANSFORM: ACS) will ensure ACS patients quickly receive cholesterol testing in the hospital and guideline-recommended therapies to reduce LDL-C in the hospital and upon discharge.
The primary goal of the TRANSFORM: ACS program will be to improve the rate of lipid-panel testing and lipid-lowering treatment intensification in ACS patients within 75 days after hospital discharge. Rapid cholesterol testing after a cardiovascular event within the hospital is hypothesized to drive initiation of lipid-lowering treatment within the first year post ACS, which could increase compliance and help patients avoid events more rapidly than current standard of care.
Two New Expert Consensus Decision Pathways Address HFrEF, Same-Day Discharge After PCI
The ACC has released two separate Expert Consensus Decision Pathways. The first provides guidance and recommendations on streamlining clinical care to achieve optimal outcomes for patients with heart failure with reduced ejection fraction (HFrEF) and the second addresses same-day discharge after PCI.
Both were published in the Journal of the American College of Cardiology.
The HFrEF Pathway aims to address 10 "pivotal" issues that remain unresolved in clinical guidelines. Specifically, the Pathway looks at how to implement guideline-directed medical therapy; how to address specific challenges like referral, care coordination, specific patient cohorts, etc.; and how to manage areas of increasing complexity, comorbidities and palliative care.
According to the authors, new therapies for HFrEF have emerged that expand the armamentarium for the treatment of patients with HFrEF since the original Pathway was published in 2017. As a result, the updated Pathway incorporates two new recommendations for patients with HFrEF, including the up-front use of sacubitril/valsartan without an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker pre-treatment.
The second recommendation is for the use of a sodium-glucose cotransporter-2 inhibitor for care of patients with HFrEF, with or without diabetes.
Recent improvements in safety and efficacy have made it possible for same-day discharge to occur following PCI with select adult patients.
The ACC's other new Pathway includes a checklist of clinical, social and facility/systems factors that clinicians can use to help determine whether a patient can be safely considered for same-day discharge.
It also highlights the benefits of same-day discharge after PCI in leading to efficient resource utilization, including increased inpatient bed availability and reduced costs related to supplies and room and board.
NCDR: Advancing Patient Care and Outcomes
"To improve patient outcomes, we must accurately measure, reliably compare, and constantly improve the quality of care we deliver," write ACC President Athena Poppas, MD, FACC, and NCDR Oversight Committee Chair Frederick A. Masoudi, MD, MSPH, FACC, in a JACC Leadership Page highlighting the ways ACC's NCDR registries are consistently delivering on this aspirational goal.
Keywords: ACC Publications, Cardiology Magazine
< Back to Listings